TORONTO, Feb. 1 /CNW/ - Patheon (TSX: PTI) a global provider of drug development and manufacturing services to the international pharmaceutical industry announced today that it will present at the 20th Annual UBS Global Healthcare Services Conference on Monday February 8, 2010. Mr. Wes Wheeler, Chief Executive Officer and President will make the formal presentation. The PowerPoint presentation will be archived and accessible on Patheon's Web site at www.patheon.com.
Patheon Inc. is a leading global provider of contract development and manufacturing services to the global pharmaceutical industry. Patheon prides itself in providing the highest quality products and services to approximately 300 of the world's leading pharmaceutical and biotechnology companies. Patheon's services range from preclinical development through commercial manufacturing of a full array of dosage forms including parenteral, solid, semi-solid and liquid forms. Patheon uses many innovative technologies including single-use disposables, Liquid-Filled Hard Capsules and a variety of modified release technologies.
Patheon's comprehensive range of fully integrated Pharmaceutical Development Services includes pre-formulation, formulation, analytical development, clinical manufacturing, scale-up and commercialization. Patheon can take customers direct to clinic with global clinical packaging and distribution services and Patheon's Quick to Clinic(TM) programs can accelerate early phase development project to clinical trials while minimizing the consumption of valuable API.
Patheon, with an integrated development and manufacturing network of 11 facilities and eight development centers across North America and Europe, strives to ensure that customer products can be launched with confidence anywhere in the world.
SOURCE Patheon Inc
For further information: For further information: Wes Wheeler, President & Chief Executive Officer, Tel: (919) 226-3200, Email: firstname.lastname@example.org; Eric Evans, Chief Financial Officer, Tel: (919) 226-3204, Email: email@example.com; Wendy Wilson, Investor Relations, Tel: (919) 226-3313, Email: firstname.lastname@example.org